



NEWS RELEASE

Contact: Arisaph Pharmaceuticals,
Inc.
Christopher Kiritsy
President and CEO
(617) 292-3322

DR. ANTONIO GOTTO, JR. TO JOIN BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD OF ARISAPH PHARMACEUTICALS

- Dr. Gotto is an internationally recognized expert in cardiovascular medicine
- Dr. Gotto joins other renowned scientists to the Scientific Advisory Board

BOSTON, MA June 30, 2006 - Arisaph Pharmaceuticals, Inc., a privately held drug discovery and design biopharmaceutical company, announced today that Antonio M. Gotto, Jr., M.D., D.Phil, has agreed to join its Board of Directors and Scientific Advisory Board (SAB). Other esteemed members of the SAB include Daniel J. Drucker, M.D., Rudolph L. Leibel, M.D., and Vijay Kumar Kuchroo, Ph.D., DVM, described separately in another press release issued today. Dr. Gotto is an internationally recognized expert in cardiovascular medicine and is expected to bring his considerable knowledge with respect to basic and clinical research to Arisaph's product development programs. Arisaph utilizes rational drug design and proprietary drug discovery platforms to develop differentiated therapies for the treatment of cardiovascular disease, cancer and diabetes.

Dr. Gotto is the Stephen and Suzanne Weiss Dean of Weill Medical College of Cornell University in New York, New York. A renowned educator, Dr. Gotto was first named dean of Weill Cornell in 1997. Previously, at Baylor College of Medicine in Houston, Texas, he was the Bob and Vivian Smith Professor and chairman of the Department of Medicine and Scientific Director of the DeBakey Heart Center and held the JS Abercrombie Professor Chair for Atherosclerosis and Lipoprotein Research. He also served as chief of the Internal Medicine Service at The Methodist Hospital in Houston.

In the field of atherosclerosis, Dr. Gotto's basic science research interests include clinical disorders of lipid transport and the structure, metabolism, and function of lipoproteins and apolipoproteins. He and his associates were the first to achieve complete synthesis of a plasma apolipoprotein (apo C-I); they also determined the complete cDNA and amino acid sequence of apo B-100, one of the largest proteins ever sequenced and a key protein in atherosclerosis. Dr. Gotto has also played a leading role in several landmark clinical trials demonstrating that cholesterol-lowering drug treatment can reduce the risk for heart disease. Dr. Gotto's postgraduate work included doctoral studies at Oxford University in England, as a Rhodes Scholar, and residency training at Massachusetts General Hospital in Boston. Dr. Gotto received his M.D. and B.A. degrees from Vanderbilt University.

"Dr. Gotto's wealth of knowledge in basic research and clinical trials will prove invaluable as we advance our lead candidates through development," said Christopher P.

Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals. Additionally, Dr. Gotto's expertise in cardiovascular medicine will complement the backgrounds of our other advisors and we expect to continue to leverage the broad-based experience of our SAB and Board of Directors to evolve the Company".

About Arisaph

Arisaph, located in Boston, Massachusetts, is an emerging drug discovery and design biopharmaceutical company with active development programs to develop differentiated therapies for diabetes, cancer and cardiovascular disease. Arisaph utilizes proprietary drug discovery platforms to develop ultra smart drugs that are efficacious and act on select targets. Arisaph has successfully applied its specificity profiling and retro-inversal chiral chemistry technology platforms to synthesize promising candidate drugs for seven different targets, including ARI-2243, a lead candidate for DPP-IV inhibition to treat type II diabetes and ARI-1778 or reverse D-4F, an orally active apo A-I mimetic peptide, being developed in collaboration with Kos Pharmaceuticals, Inc. to treat atherosclerosis. Through a licensing agreement with Tufts University, the Company has exclusive worldwide rights to several important issued patents in the diabetes area and several pending patents that have utility for the treatment of cancer and cardiovascular disease.

Certain statements in this press release, including statements regarding the Company's research and development efforts, the Company's ability to benefit from the participation of its Board of Directors and scientific advisors, and the Company's ability to successfully capitalize on the early stage research are forward-looking and are subject to risks and uncertainties. These risks and uncertainties include risks and uncertainties related to: our ability to discover and develop new compounds and products using a novel approach to drug discovery; the early stage of all of our discovery and development efforts; our ability successfully to complete preclinical and clinical development of our products; our ability to obtain and maintain regulatory approvals for our products; competition from other technologies and technologies similar to ours; obtaining, maintaining and protecting intellectual property utilized by our products; changes in legislation and regulations affecting our products and potential product candidates; our need to obtain additional funding to support our business activities; our dependence on collaborators and other third parties for development, manufacture, marketing, sales and distribution of products; the ability of our licenses to achieve developmental, regulatory and other milestones and to commercialize their products; the effect of conditions in the pharmaceutical industry and the economy in general, as well as certain other risks and uncertainties.